SCLC, Limited Stage

Explore clinical trials studying SCLC, Limited Stage. Study availability and eligibility vary by location and protocol.

7 public trials 7 recruiting studies

Refine in advanced search Browse all conditions

SCLC, Limited Stage trial results

Recruiting

A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC

NCT07815223

Conditions: SCLC, Limited Stage
Locations: Yantai Yuhuangding Hospital Yantai, Shandong, China

View Trial Details

Recruiting

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

NCT07508852

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Disease, +15 more
Locations: Peking university first hospital nuclear medicine Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

NCT07309211

Conditions: SCLC, Limited Stage
Locations: Cancer Hospital of Shandong First Medical University Jinan, China

Nanjing Chest Hospital Nanjing, China

The First Affiliated Hospital with Nanjing Medical University Nanjing, China

The affiliated hospital of qingdao university Qingdao, China

View Trial Details

Recruiting

Omitting CTV for Primary Tumor in LS-SCLC

NCT07008716

Conditions: Disease Attributes, Disease Progression, Pathologic Processes, +7 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

Zhejiang Provincial Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Recruiting

Lung Cancer Registry

NCT04654364

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations: Universitätsklinik für Innere Medizin III, PMU Salzburg Salzburg, State of Salzburg, Austria

Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken Innsbruck, Tyrol, Austria

Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie Linz, Upper Austria, Austria

View Trial Details

Recruiting

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06911606

Conditions: SCLC, Limited Stage
Locations: Guangdong Provincial People's Hospital Guangzhou, Guangdong, China

View Trial Details

Recruiting

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

NCT06371482

Conditions: SCLC, Limited Stage
Locations: Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China

View Trial Details

SCLC, Limited Stage

SCLC, Limited Stage trial results

A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

Omitting CTV for Primary Tumor in LS-SCLC

Lung Cancer Registry

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Related conditions